Randomised, double-blind crossover comparison of once-daily captopril and lisinopril in patients with mild to moderate hypertension--a community-based study. Hunter Hypertension Research Group.
Of twenty-five patients with mild to moderate hypertension, recruited and managed in the community, seventeen responded fully to, and completed a randomised cross-over study of, captopril (ceiling dose 100 mg) compared with lisinopril (ceiling dose 40 mg) both given as a single daily dose. Mean supine and standing blood pressures measured at the end of the dose interval were significantly reduced compared to placebo by both compounds at three and six weeks. However, a consistent, significant increase in blood pressure occurred between three and six weeks in both arms of the study despite good and unchanged compliance with a fixed dose of each medication. Both captopril and lisinopril were well tolerated. Drug-related cough was the principal adverse effect.
D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D002216:Captopril / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004151:Dipeptides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D017706:Lisinopril; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D013810:Therapeutic Equivalency
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D004151:Dipeptides; D002216:Captopril; D017706:Lisinopril